Centogene (CNTG) рд╕реНрдЯреЙрдХ
рд╕рд╛рд░реНрд╡рдЬрдирд┐рдХ рд░реВрдк рд╕реЗ рд╕реВрдЪреАрдмрджреНрдз рдХрдВрдкрдиреАред рдпрд╣рд╛рдБ рдХреАрдордд, рд╡реНрдпрд╡рд╕рд╛рдп рдХрд╛ рд╕рдВрдХреНрд╖рд┐рдкреНрдд рд╡рд┐рд╡рд░рдг рдФрд░ рд╕рд┐рддрдВрдмрд░ 2026 рдореЗрдВ Centogene рдХреЗ рдмрд╛рд░реЗ рдореЗрдВ рдЬрд╛рдирдиреЗ рдпреЛрдЧреНрдп рдмрд╛рддреЗрдВ рджреА рдЧрдИ рд╣реИрдВред
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.